biomedicina slovenica

re="Haemostasis" : 65

  1. Bedenčič M; Božič M; Stegnar M
    Venous thromnoembolism associated polymorphisms in Slovene population
    2007 ►
  2. Vizintin-Cuderman T; Božič M; Antovič A; Peternel P; Stegnar M
    Overall haemostasis potential in patients with venous thrombosis before, during and after anticoagulant treatment
    2007 ►
  3. Kozak M; Božič M; Stegnar M
    Matrix metalloproteinase-3, tissue inhibitor of metalloproteinases-1 and warfarin treatment
    2007 ►
  4. Božič M; Rakuša M; Stegnar M
    Us biological variation of plateled function tests too high reliable detection of aspirin resistance?
    2007 ►
  5. Bedenčič M; Blinc A; Božič M; Stegnar M; Kozak M; Šabovič M; Poredoš P; Kravos A; Barbič-Žagar B; Pohar-Perme M; Stare J
    Association of haemostatic and inflammatory markers with future ischemic cardiovascular events in patients with peripheral arterial disease - initial laboratory results of the prevention of ischemic events in patients with peripheral arterial disease (PID)
    2009 ►
  6. Bedenčič M; Zemljič E; Božič M; Peternel P; Stegnar M
    CYP2C9 genotypes and response to warfarin during initial anticoagulation in patients with atrial fibrillation
    2009 ►
  7. Poller L; Keown M; Ibrahim S; Lowe G; Moia M; Turpie AG; Roberts C; Peternel P; Krevel B; Stegnar M
    An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage
    2008 ►
  8. Poller L; Keown M; Ibrahim S; Van den Besselaar AMHP; Roberts C; Stevenson K; Tripodi A; Pattison A; Peternel P; Stegnar M
    Comparison of local International sensitivity index calibration and 'Direct INR' methods in correction of locally reported International normalized ratios: an international study
    2007 ►
  9. Urlep-Šalinović Vera; Lokar L
    Thromboprophylaxis with LDH or LMWH in gynaecological patients with malignancy
    2003 ►
  10. Urlep-Šalinović Vera; Pajk J
    The rational use of blood in two slovenian hospitals
    2003 ►
  11. Peternel P; Cvelbar-Marinko T; Goršič-Tomažič K; Stegnar M; Salobir-Pajnič B; Uhrin P; Binder BR
    Activated protein C resistance among patients with deep vein thrombosis in Slovenia
    1996 ►
  12. Vižintin T; Plausteiner K; Božič M; Peternel P; Peterlin B; Stegnar M
    Markers of coagulation activation in symptomatic and asymptomatic subjects with thrombophilia
    2002 ►
  13. Lokar L; Urlep-Šalinović V; Zagradišnik B; Kokalj-Vokač N
    Correlation beetwen ProC Global assay and coagulation inhibitor assays
    2001 ►
  14. Samama Meyer Michel; Desnoyers Pierre; Gerotziafas Grigoris T
    Low molecular weight heparins: a comparative review of pharmacodynamic, clinical pharmacology
    2001 ►
  15. Samama MM; Kher A
    Anticoagulation: the old and new
    2001 ►
  16. Scholz T; Krause S; Finkelberg L; Loesche W
    Detection of small platelet aggregates and their inhibition by glycoprotein IIb/IIIa antagonists in a laser aggregometer
    2001 ►
  17. Niessner A; Kaun C; Christiansen G; Pedersen AS; Simon S; Zorn G; Georgopoulos A; Graninger W; Huber K; Wojta J
    Outer membrane protein 11 (OMP 11) and OMP 15 of Chlamydia pneumoniae induce the chemokine interleukin-8 (IL-8) and the pro-inflammatory cytokine IL-6 in human endothelial cells in vitro
    2001 ►
  18. Weiss T; Macfelda K; Kaun C; Zorn G; Kapeller B; Springer C; Bialy J; Losert UM; Breuss JM; Binder BR
    Inflammatory cytokines and growth factors regulate plasminogen activator inhibitor-1 (PAI-1) in human adult cardiac myocytes (HACM)
    2001 ►
  19. Miles LA; Green M; Gong A; Jardi M; Felez J
    Monoclonal antibodies detect receptor-induced binding sites (RIBS) in plasminogen induced by its interaction with cells
    2001 ►
  20. Barrowcliffe TW; Jardi M; Cancelas JA; Rabaneda M; Fabregas P; Felez J
    Procoagulant activity of T lymphoblastoid cells due to exposure of negatively charged phospholipid
    2001 ►
  21. Barrowcliffe TW; Rabaneda M; Gray E; Felez J
    Procoagulant activity of activated endothelial cells - the importance of negatively charged phospholipids
    2001 ►
  22. Speidl WS; Graf S; Nikfardjam M; Niessner A; Zorn G; Wojta J; Huber K
    High sensitivity C-reactive protein predicts risk for further coronary events in stable patients with premature coronary artery disease
    2001 ►
  23. Hiltunen L; Paunio M; Kaaja R; Vahtera E; Krusius T; Rasi V
    A prospective nested case control study of thromboembolic complications of pregnancy
    2001 ►
  24. Kuismanen K; Salonvaara M; Mononen T; Riikonen P
    Treatment of a newborn with neonatal purpura fulminans in a family with hereditary type II protein C deficiency
    2001 ►
  25. Niessner A; Hornykewycz S; Joerg M; Zorn G; Graf S; Binder BR; Huber K
    Increased risk of restenosis after successful percutaneous transluminal coronary angioplasty in patients with permanently elevated anticardiolipin antibodies
    2001 ►
  26. Michiels JJ; Kasbergen HAA; Trienekens PH
    Evidence for safe exclusion of deep vein thrombosis (DVT- by a rapid ELISA D-dimer test in 434 consecutive outpatients with suspected DVT
    2001 ►
  27. Michiels JJ; Posthuma W; Ponjee GAE; Stef E; Quint WG; van Doorn LJ
    DNA typing for thrombophilia-related factor V leiden and prothrombing G20210A mutations by multiplex PCR and reverse hybridisation LiPA in 473 thrombosis patients
    2001 ►
  28. Furlan M
    New strategies in diagnosis and treatment of thrombocitic thrombocytopenic purpura
    2001 ►
  29. Vermylen J
    Heparin-induced thrombocytopenia
    2001 ►
  30. Prandoni P
    The optimal treatment of venous thrombosis
    2001 ►
  31. Vermylen J
    Platelet glycoprotein receptor antagonists
    2001 ►
  32. Felez J
    Cell surface associated fibrinolysis
    2001 ►
  33. Blinc A
    Transport of fibrinolytic agents as a rate-limiting step in fibrinolysis and thrombolysis
    2001 ►
  34. Palareti G
    Laboratory and therapeutic quality control of anticoagulant treatment: an update
    2001 ►
  35. Collen D; Lijnen HR
    Recent developments in thrombolytic therapy
    2001 ►
  36. Lijnen HR
    Molecular interactions between the plasminogen/plasmin and matrix metalloproteinase systems
    2001 ►
  37. Lowe GDO
    Lipoprotein(a) and cardiovascaular disease
    2001 ►
  38. Lowe GDO
    Fibrinogen, fibrin D-dimer and cardiovascular disease
    2001 ►
  39. Juhan-Vague I; Alessi MC; Morange PE
    Hypofibrinolysis and increased PAI-I are linked to atherothrombosis via insulin resistance and obesity
    2001 ►
  40. Iacoviello L; Donati MB
    Gene-environment interactions: the example of coagulation factors
    2001 ►
  41. Castoldi E; Bernardi F
    Factor V markers for the detection of genetic components of APC resistance in venous thrombosis
    2001 ►
  42. de Gaetano G; Rotondo S
    Mediterranean diet and cardiovascular disease
    2001 ►
  43. Wiman B
    Fibrinolytic factors in connection with cardiovascular disease
    2001 ►
  44. Pabinger-Fascing I
    Thrombophilia - a multigene defect
    2001 ►
  45. Bertina R
    Identification of molecular risk markers for thrombosis
    2001 ►
  46. Schved JF; Giansily M
    Tissue factor and tissue factor pathway inhibitor: from fundamental to clinic
    2001 ►
  47. Binder BR
    Arterial thrombosis. Pathomechanism, prediction and therapy
    2001 ►
  48. Geiger M
    Protein C inhibitor
    2001 ►
  49. Perrier A
    D-dimer testing in suspected venous thromboembolism
    2001 ►
  50. Ten Cate H
    Markers of blood coagulation activation
    2001 ►
  51. Gaffney PJ
    Fibrin degradation products. A review of structures found in vitro and in vivo
    2001 ►
  52. Galli M
    Antiphospholipid antibodies: predictive value of laboratory tests
    2001 ►
  53. Kluft C
    Standardization of fibrinolysis methods
    2001 ►
  54. Bazzoni G; Martinez-Estrada OM; Dejana E
    Molecular architecture of interendothelial junctions
    2001 ►
  55. Levy-Toledano S
    Platelet signal transduction pathways: could we organize them into a "hierarchy"
    2001 ►
  56. Poredoš P
    Endothelial dysfunction in the pathogenesis of atherosclerosis
    2001 ►
  57. Peternel P; Terbižan M; Tratar G; Božič M; Salobir B; Stegnar M
    Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low molecular weight heparin
    2000 ►
  58. Stegnar M; Keber D
    Heparin therapy and plasminogen activator release during venous occlusion
    1982 ►
  59. Keber D; Stegnar M
    Responsibility of hydrostatic pressure for the difference between arm and leg fibrinolytic potential
    1982 ►
  60. Keber D; Stegnar M
    The increase of leg fibrinolytic potential after reduction of hydrostatic stimulus
    1982 ►
  61. Stegnar M; Božič M; Fermo I; Ritonja A; D'Angelo A; Peternel P
    Association of mild hyperhomocysteinemia with fibrinolysis and resistance to activated protein C in venous thromboembolism
    1998 ►
  62. Keber I; Lavrenčič A; Gužič B
    Physical training improves endothelium-dependent dilation in patients with polymetabolic syndrome, fibrinolytic factors remain unchanged
    1998 ►
  63. Keber Dušan
    Overview of the fibrinolytic system in 1995
    1995 ►
  64. Keber I; Keber D
    Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis
    1992 ►
  65. Blinc A; Keber D; Lahajnar G; Zupančič I; Zorec-Karlovšek M; Demšar F
    Magnetic resonance imaging of retracted and nonretracted blood clots during fibrinolysis in vitro
    1992 ►

Nova poizvedba      Pripombe      Na vrh strani                        Inštitut za biostatistiko in medicinsko informatiko